AstraZeneca's pipeline premium erodes by 2027-06-30

The company's historical pipeline premium is tied to consistent late-stage trial successes. The Wainua failure, combined with broader market scrutiny, could lead to a re-rating of AstraZeneca's valuation relative to peers, reducing its premium by at least 15%.

valuation · Prediction Market

Implied probability (Yes)

60%

Closes

2027-06-30

More valuation markets

• SpaceX IPO valuation drops below $200B post-xAI dissolution — 60% Yes
• Lovable’s $13.2B valuation triggers competitor valuations rebound by 2026-12-31 — 60% Yes
• Lovable's valuation exceeds $15B within 12 months of Series funding close — 70% Yes
• Mistral AI valuation reaches $30B+ by December 2026 — 70% Yes
• Mistral AI's valuation exceeds $30B by 2027-Q1 — 60% Yes
• OpenAI to exceed $100B valuation by December 2026 — 72% Yes
• Helsing's valuation exceeds $20B by end of 2027 — 60% Yes
• Phia's valuation drops by 30% within 6 months due to scandal — 80% Yes

Browse all valuation markets →